# Cydan II

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cydan-ii

- Industry: Pharmaceuticals
- Headquarters: Cambridge, US
- Website: www.cydanco.com
- Total disclosed funding: $26M
- Latest round: Series A (Oct 1, 2013)
- Investors on record: 5

## About

Cydan II, Inc. is a biopharmaceutical company focused on advancing innovative therapies for rare genetic disorders. The firm is dedicated to identifying and developing transformative treatments for unmet medical needs.Cydan II, Inc. specializes in developing therapies aimed at rare genetic diseases. Founded in 2013, the company is headquartered in Cambridge, US. Chris Adams serves as the CEO. The firm has undergone a strategic focus on rare diseases since its inception. In October 2017, Cydan II, Inc. raised USD 34.00 mn in a funding round led by New Enterprise Associates, with participation from Alexandria Venture Investments, Longitude Capital, Lundbeckfond Ventures, and Pfizer Venture Investments. This funding round marked the firm’s total raised amount, which is USD 34.00 mn.Cydan II, Inc. focuses on developing therapeutic solutions for rare genetic disorders. Their offerings are centered around pioneering drug candidates that target specific genetic mutations, aiming to address critical gaps in treatment options for affected patients. The company’s research initiatives are geared towards providing innovative and effective therapies to improve the quality of life for those impacted by rare diseases.Cydan II, Inc. generates revenue primarily through partnerships and collaborations with pharmaceutical companies aimed at developing and commercializing its therapeutic products. Their financial structure is designed to support ongoing research and clinical development through strategic collaborations, driving their commitment to rare diseases without disclosing specific figures on consumer subscriptions or direct-to-consumer transactions.Cydan II, Inc. plans to leverage its recent funding of USD 34.00 mn to enhance its drug development pipeline, focusing on the advancement of new product candidates targeting rare genetic disorders. The firm is strategizing to expand its market reach into Europe and Asia by 2025, aiming to establish partnerships with local biopharmaceutical firms. This expansion will facilitate access to new patient populations and accelerate the development of their innovative therapies, ensuring they meet the needs of a broader audience.

## Funding rounds

- Series A, Oct 1, 2013, $10M — New Enterprise Associates, Alexandria Venture Investments, Bay City Capital, Lundbeckfond Ventures, Pfizer Venture Investments
- Series A, Apr 11, 2013, $16M — New Enterprise Associates, Alexandria Venture Investments, Pfizer Venture Investments

## Investors

- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series A
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series A
- Pfizer Venture Investments (https://capitalatlas.ai/funds/pfizer-venture-investments) — Series A
- Bay City Capital (https://capitalatlas.ai/funds/bay-city-capital) — Series A
- Lundbeckfond Ventures (https://capitalatlas.ai/funds/lundbeckfond-ventures) — Series A